Centene Corp (CNC)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $35.28B
Last updated: Nov 17, 2026 at 11:05 AM ET
Centene Corp (CNC) Earnings: Report Dates and Results
Centene (CNC) is expected to report earnings on Feb 4, 2027. In the quarter ended Sep 30, 2026, Centene reported EPS of $0.58, above the $0.07 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CNC has an expected report date of Feb 4, 2027.
CNC Earnings Call
The latest CNC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CNC beat 34, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $50.65B, up 1.9% from $49.69B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.58 | $0.07 | $0.00 - $0.33 | +728.57% | Beat | +16.0% | 19 | 0 up, 1 down | Oct 27, 2026 | $50.65B |
| Jun 30, 2026 | $2.51 | $0.89 | $0.41 - $1.94 | +182.02% | Beat | N/A | 19 | 0 up, 0 down | Jul 28, 2026 | $53.58B |
| Mar 31, 2026 | $3.37 | $2.13 | $0.41 - $2.89 | +58.22% | Beat | +16.2% | 18 | 2 up, 4 down | Apr 28, 2026 | $49.94B |
| Dec 31, 2025 | -$1.19 | -$1.22 | -$1.30 - -$0.99 | +2.46% | Beat | -248.7% | 18 | 1 up, 2 down | Feb 6, 2026 | $49.73B |
| Sep 30, 2025 | $0.50 | -$0.16 | -$0.59 - $0.05 | +412.50% | Beat | -69.1% | 18 | 1 up, 0 down | Oct 29, 2025 | $49.69B |
| Jun 30, 2025 | -$0.16 | $0.21 | -$1.02 - $1.54 | -176.19% | Miss | -106.6% | 14 | N/A | Jul 25, 2025 | $48.74B |
| Mar 31, 2025 | $2.90 | $2.52 | $1.96 - $2.74 | +15.08% | Beat | +28.3% | 15 | 6 up, 0 down | Apr 25, 2025 | $46.62B |
| Dec 31, 2024 | $0.80 | $0.49 | $0.43 - $0.58 | +63.27% | Beat | +77.8% | 16 | 2 up, 2 down | Feb 4, 2025 | $40.80B |
| Sep 30, 2024 | $1.62 | $1.41 | $1.27 - $1.55 | +14.89% | Beat | -19.0% | 15 | 0 up, 0 down | Oct 25, 2024 | $42.02B |
| Jun 30, 2024 | $2.42 | $2.09 | $1.80 - $2.44 | +15.79% | Beat | +15.2% | 17 | 5 up, 0 down | Jul 26, 2024 | $39.84B |
| Mar 31, 2024 | $2.26 | $2.08 | $1.90 - $2.26 | +8.65% | Beat | +7.1% | 17 | 0 up, 0 down | Apr 26, 2024 | $40.41B |
| Dec 31, 2023 | $0.45 | $0.44 | $0.38 - $0.55 | +2.27% | Beat | -47.7% | 14 | 1 up, 0 down | Feb 6, 2024 | $39.46B |
| Sep 30, 2023 | $2.00 | $1.54 | $1.26 - $1.80 | +29.87% | Beat | +53.8% | 15 | 4 up, 0 down | Oct 24, 2023 | $38.04B |
| Jun 30, 2023 | $2.10 | $2.05 | $1.69 - $2.53 | +2.44% | Beat | +18.6% | 19 | 2 up, 1 down | Jul 28, 2023 | $37.61B |
| Mar 31, 2023 | $2.11 | $2.10 | $1.77 - $3.79 | +0.48% | Beat | +15.3% | 18 | 1 up, 0 down | Apr 25, 2023 | $38.89B |
| Dec 31, 2022 | $0.86 | $0.84 | $0.78 - $1.37 | +2.38% | Beat | -14.9% | 17 | 0 up, 0 down | Feb 7, 2023 | $35.56B |
| Sep 30, 2022 | $1.30 | $1.23 | $1.12 - $1.40 | +5.69% | Beat | +3.2% | 18 | 1 up, 0 down | Oct 25, 2022 | $35.87B |
| Jun 30, 2022 | $1.77 | $1.59 | $1.05 - $1.79 | +11.32% | Beat | +41.6% | 19 | 12 up, 0 down | Jul 26, 2022 | $35.94B |
| Mar 31, 2022 | $1.83 | $1.69 | $1.60 - $1.84 | +8.28% | Beat | +12.3% | 17 | 1 up, 0 down | Apr 26, 2022 | $37.19B |
| Dec 31, 2021 | $1.01 | $0.97 | $0.95 - $1.15 | +4.12% | Beat | +119.6% | 17 | 1 up, 0 down | Feb 8, 2022 | $32.57B |
| Sep 30, 2021 | $1.26 | $1.23 | $0.74 - $1.62 | +2.44% | Beat | 0.0% | 18 | 1 up, 2 down | Oct 26, 2021 | $32.41B |
| Jun 30, 2021 | $1.25 | $1.37 | $1.15 - $2.15 | -8.76% | Miss | -47.9% | 19 | N/A | Jul 27, 2021 | $31.02B |
| Mar 31, 2021 | $1.63 | $1.53 | $1.35 - $1.77 | +6.54% | Beat | +89.5% | 14 | N/A | Apr 27, 2021 | $29.98B |
| Dec 31, 2020 | $0.46 | $0.47 | $0.36 - $0.54 | -2.13% | Miss | -37.0% | 15 | N/A | Feb 9, 2021 | $28.29B |
| Sep 30, 2020 | $1.26 | $0.96 | $0.89 - $1.05 | +31.25% | Beat | +31.3% | 18 | N/A | Oct 27, 2020 | $29.09B |
| Jun 30, 2020 | $2.40 | $2.43 | $2.38 - $2.58 | -1.23% | Miss | +79.1% | 18 | N/A | Jul 28, 2020 | $27.71B |
| Mar 31, 2020 | $0.86 | $0.99 | $0.88 - $1.34 | -13.13% | Miss | -38.1% | 17 | N/A | Apr 28, 2020 | $26.02B |
| Dec 31, 2019 | $0.73 | $0.73 | $0.66 - $0.80 | 0.00% | In line | +5.8% | 21 | N/A | Feb 4, 2020 | $18.86B |
| Sep 30, 2019 | $0.96 | $0.95 | $0.91 - $1.02 | +1.05% | Beat | +6.7% | 19 | N/A | Oct 22, 2019 | $18.98B |
| Jun 30, 2019 | $1.34 | $1.24 | $1.15 - $1.31 | +8.06% | Beat | +48.9% | 18 | N/A | Jul 23, 2019 | $18.36B |
| Mar 31, 2019 | $1.39 | $1.35 | $1.04 - $1.41 | +2.96% | Beat | +27.5% | 20 | N/A | Apr 23, 2019 | $18.44B |
| Dec 31, 2018 | $0.69 | $0.66 | $0.62 - $0.71 | +4.55% | Beat | +40.8% | 21 | N/A | Feb 5, 2019 | $16.56B |
| Sep 30, 2018 | $0.90 | $0.89 | $0.84 - $0.91 | +1.12% | Beat | +32.4% | 21 | N/A | Oct 23, 2018 | $16.18B |
| Jun 30, 2018 | $0.90 | $0.88 | $0.85 - $1.00 | +2.27% | Beat | +12.5% | 20 | N/A | Jul 24, 2018 | $14.18B |
| Mar 31, 2018 | $1.09 | $0.97 | $0.57 - $1.05 | +12.37% | Beat | +94.6% | 16 | N/A | Apr 24, 2018 | $13.19B |
| Dec 31, 2017 | $0.49 | $0.46 | $0.42 - $0.49 | +6.52% | Beat | -18.3% | 19 | N/A | Feb 6, 2018 | $12.81B |
| Sep 30, 2017 | $0.68 | $0.62 | $0.56 - $0.67 | +9.68% | Beat | +21.4% | 16 | N/A | Oct 24, 2017 | $11.90B |
| Jun 30, 2017 | $0.80 | $0.64 | $0.58 - $0.90 | +25.00% | Beat | +23.1% | 19 | N/A | Jul 25, 2017 | $11.95B |
| Mar 31, 2017 | $0.56 | $0.52 | N/A | +7.69% | Beat | +51.4% | N/A | N/A | Apr 25, 2017 | $11.72B |
| Dec 31, 2016 | $0.60 | $0.55 | N/A | +9.09% | Beat | +25.0% | N/A | N/A | Feb 7, 2017 | $11.91B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.05, down 71.1% from the year before. It was $2.18 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.05 | -71.1% |
| Dec 31, 2024 | $7.10 | +6.6% |
| Dec 31, 2023 | $6.66 | +15.6% |
| Dec 31, 2022 | $5.76 | +11.8% |
| Dec 31, 2021 | $5.15 | +3.4% |
| Dec 31, 2020 | $4.98 | +12.7% |
| Dec 31, 2019 | $4.42 | +23.5% |
| Dec 31, 2018 | $3.58 | +41.5% |
| Dec 31, 2017 | $2.53 | +16.1% |
| Dec 31, 2016 | $2.18 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,300 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,296 | 17 | |
| 2026Q2 | Jun 30, 2026 | 9,861 | 16 | |
| 2026Q1 | Mar 31, 2026 | 8,708 | 17 | |
| 2025Q4 | Dec 31, 2025 | 9,426 | 15 | |
| 2025Q3 | Sep 30, 2025 | 8,561 | 15 | |
| 2025Q2 | Jun 30, 2025 | 9,836 | 15 | |
| 2025Q1 | Mar 31, 2025 | 8,810 | 18 | |
| 2024Q4 | Dec 31, 2024 | 6,875 | 16 |
2026Q3 Earnings Call
Opening remarks
Jennifer Lynch Gilligan Senior Vice President, Investor Relations Thank you, Rocco, and good morning, everyone. Thank you for joining us on our third quarter 2026 earnings results conference call. Sarah London, Chief Executive Officer, and Drew Asher, Executive Vice President and Chief Financial Officer of Centene, will host this morning's call, which can also be accessed through our website at centene.com. Any remarks that Centene may make about future expectations, plans, and prospects constitute forward-looking statements for the purpose of the Safe Harbor provision under the Private Securities Litigation Reform Act of 2000. Specifically, our commentary on our full-year 2026 outlook, including the drivers of such outlook, are forward-looking statements. Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our third quarter 2026 press release and other public SEC filings, which are available on the company's website under the Investors section. Centene anticipates that subsequent events and developments may cause its estimates to change. While the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. The call will also refer to certain non-GAAP measures. A reconciliation of these measures with the most directly comparable GAAP measures can be found in our third quarter 2026 press release. With that, I would like to turn the call over to our CEO, Sarah London. Sarah?
Sarah London CEO Thanks, Jennifer, and thank you all for joining us to review Centene's third quarter results. This morning, we reported third quarter adjusted diluted earnings per share of $0.58, ahead of our previous expectations. These results, driven by outperformance in our Medicare segment and in-line performance from our Medicaid and commercial businesses, support an improved full-year financial outlook. We now expect 2026 adjusted diluted earnings per share of more than $5.20. As we remain focused on disciplined execution to finish the year strong, we are excited to carry the positive momentum we are producing across our businesses into 2027. Let's unpack the results by business line, starting with Medicaid. Our Medicaid business is right on track for the quarter, reflecting the positive rate actions highlighted during our second quarter call and effective execution against key quality and affordability initiatives, including member and provider engagement, network management, and a diverse portfolio of fraud, waste, and abuse interventions. We reported a Medicaid HBR of 93.6%, improving sequentially by 30 basis points from Q2 and keeping pace with our trajectory to achieve a full-year Medicaid HBR of 93.5%.
Frequently Asked Questions About CNC
When is Centene's next earnings date?
Centene's next earnings report is expected for Feb 4, 2027.
Did CNC beat earnings estimates last quarter?
Yes. Centene reported EPS of $0.58 for the quarter ended Sep 30, 2026, above the $0.07 estimate, a 728.57% surprise.
What EPS do analysts expect from CNC next quarter?
The consensus EPS estimate for Centene for the quarter ending Dec 31, 2026 is -$1.16 from 22 analysts, with estimates from -$1.24 to -$0.99.
How often does CNC beat earnings estimates?
Centene beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +160.74%.
CNC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts